Trek Therapeutics Combats HCV Globally
Robert Hindes, MD, led Phase 2 and 3 programs for sofosbuvir, a HCV polymerase inhibitor, while serving as vice president of clinical development at Pharmasset.

Established in 2014 and cofounded by chief medical officer Robert Hindes, MD, Trek Therapeutics aims to create safe and effective infectious diseases medicines for patients worldwide.

Since its inception, Trek Therapeutics has been in the process of developing a hepatitis C virus (HCV) combination therapy with a treatment period of 12 weeks or less. HCV is an infection that leads to liver disease and is the leading cause of liver cancer in the United States. The two drugs that Trek has combined to treat HCV include faldaprevir (a protease inhibitor) and TD-6450 (a NSSA inhibitor). In October 2015, Trek Therapeutics began conducting double-blind, randomized clinical trials to test the efficacy and safety of this combination.

In developing countries with limited access to medicines and clinics, people often die from treatable diseases. Trek Therapeutics’ mission is to create HCV treatments that are affordable and available to anyone with chronic infection.
Trek Therapeutics Combats HCV Globally
0
9
0
Published:

Trek Therapeutics Combats HCV Globally

Robert Hindes, MD, led Phase 2 and 3 programs for sofosbuvir, a HCV polymerase inhibitor, while serving as vice president of clinical development Read More
0
9
0
Published:

Creative Fields